NZ755599A - Apoc-ii mimetic peptides - Google Patents

Apoc-ii mimetic peptides

Info

Publication number
NZ755599A
NZ755599A NZ755599A NZ75559918A NZ755599A NZ 755599 A NZ755599 A NZ 755599A NZ 755599 A NZ755599 A NZ 755599A NZ 75559918 A NZ75559918 A NZ 75559918A NZ 755599 A NZ755599 A NZ 755599A
Authority
NZ
New Zealand
Prior art keywords
peptide
apoc
mimetic
seq
mimetic peptide
Prior art date
Application number
NZ755599A
Other languages
English (en)
Inventor
Alan Remaley
Soumitra Ghosh
Madhav Devalaraja
Chih-Hung Lo
Denis Sviridov
Anna Wolska
Original Assignee
Novo Nordisk As
The Us Secretary Department Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, The Us Secretary Department Of Health & Human Services filed Critical Novo Nordisk As
Publication of NZ755599A publication Critical patent/NZ755599A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ755599A 2017-01-19 2018-01-19 Apoc-ii mimetic peptides NZ755599A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (1)

Publication Number Publication Date
NZ755599A true NZ755599A (en) 2022-12-23

Family

ID=62908746

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ755599A NZ755599A (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Country Status (14)

Country Link
US (2) US11136372B2 (https=)
EP (1) EP3571216A4 (https=)
JP (2) JP7353973B2 (https=)
KR (1) KR102700862B1 (https=)
CN (1) CN110831957B (https=)
AU (1) AU2018210404B2 (https=)
BR (1) BR112019014707A2 (https=)
CA (1) CA3050106A1 (https=)
IL (2) IL268093B2 (https=)
MX (1) MX2019008529A (https=)
NZ (1) NZ755599A (https=)
SG (2) SG10201911974UA (https=)
TW (2) TWI788323B (https=)
WO (1) WO2018136803A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008529A (es) 2017-01-19 2020-02-07 Us Health Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
US20240309065A1 (en) * 2021-06-23 2024-09-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Short apoc-ii mimetic peptides and methods of use
IL316418A (en) * 2022-05-05 2024-12-01 Us Health Short apolipoprotein E mimetic peptides and methods of use
EP4565251A1 (en) * 2022-08-07 2025-06-11 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
AU2002362612B2 (en) 2001-09-28 2007-11-15 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
JP2007504285A (ja) * 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
WO2005058938A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JPWO2005080348A1 (ja) * 2004-02-19 2007-08-02 萬有製薬株式会社 新規スルホンアミド誘導体
CN101076541A (zh) 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
US8575307B2 (en) * 2005-06-29 2013-11-05 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
WO2011040654A1 (ko) 2009-09-30 2011-04-07 서울대학교산학협력단 아포리포프로테인 에이１ 모방 펩타이드，및 이를 포함하는 고지혈증 및 이와 관련된 질환 치료제
BR112015010276A2 (pt) * 2012-11-06 2019-10-15 Hoffmann La Roche peptídeos miméticos
MX2019008529A (es) 2017-01-19 2020-02-07 Us Health Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Also Published As

Publication number Publication date
US11827690B2 (en) 2023-11-28
WO2018136803A1 (en) 2018-07-26
US20210324043A1 (en) 2021-10-21
IL268093B2 (en) 2024-07-01
EP3571216A1 (en) 2019-11-27
IL268093B1 (en) 2024-03-01
US20200140522A1 (en) 2020-05-07
CN110831957A (zh) 2020-02-21
EP3571216A4 (en) 2020-11-04
TW202130652A (zh) 2021-08-16
SG10201911974UA (en) 2020-02-27
AU2018210404B2 (en) 2022-01-27
CA3050106A1 (en) 2018-07-26
JP2023116739A (ja) 2023-08-22
TW201835097A (zh) 2018-10-01
KR102700862B1 (ko) 2024-08-30
BR112019014707A2 (pt) 2020-04-07
WO2018136803A8 (en) 2019-08-01
SG11201906422VA (en) 2019-08-27
IL279831A (en) 2021-03-01
TWI788323B (zh) 2023-01-01
US11136372B2 (en) 2021-10-05
CN110831957B (zh) 2024-02-09
JP2020511425A (ja) 2020-04-16
MX2019008529A (es) 2020-02-07
IL268093A (en) 2019-09-26
JP7353973B2 (ja) 2023-10-02
KR20190121305A (ko) 2019-10-25
AU2018210404A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
EP1853620B1 (en) Antimicrobial hexapeptides
NZ755599A (en) Apoc-ii mimetic peptides
Laverty et al. The potential of antimicrobial peptides as biocides
Di Grazia et al. Temporins A and B stimulate migration of HaCaT keratinocytes and kill intracellular Staphylococcus aureus
EP4461811A3 (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
Kyriakopoulos et al. Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends
JP2021506899A (ja) ボツリヌス毒素細胞結合ドメインポリペプチドおよび線維症関連障害の処置のための使用方法
NZ596778A (en) Glucose-regulating polypeptides and methods of making and using same
EA039105B1 (ru) Катионные нейротоксины
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
Puri et al. Immunomodulatory role of neuropeptides in the cornea
Michael Conlon et al. Design of potent, non‐toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin‐8 and peptide XT‐7
HRP20090597T1 (hr) Muteini čimbenika rasta fibroblasta 21
KR20180002710A (ko) 항균 요법
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
NZ597306A (en) Mesenchymal stem cell differentiation
RU2013151875A (ru) Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
Chen et al. In vitro and in vivo studies on the antibacterial activity and safety of a new antimicrobial peptide dermaseptin-AC
Ouyang et al. High therapeutic index α-helical AMPs and their therapeutic potential on bacterial lung and skin wound infections
EP3536325A1 (en) Method for promoting wound healing
EP1969003B8 (en) Uses of a NEUROTROPHIC FACTOR PROTEIN
CA2533753A1 (en) Drug for cancer therapy
JP2012507278A5 (https=)
CA2516458C (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Yang et al. Deleting the first disulphide bond in an arenicin derivative enhances its expression in Pichia pastoris

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: THE UNITED STATES OF AMERICA, US

Effective date: 20210921

Owner name: NOVO NORDISK A/S, DK

Effective date: 20210921

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2025 BY ANAQUA SERVICES

Effective date: 20231220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2026 BY ANAQUA SERVICES

Effective date: 20241219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2027 BY ANAQUA SERVICES

Effective date: 20251217